Larisa H. Cavallari
 |
Larisa H. Cavallari, PharmD, BCPS, FCCP Associate Professor Hospital Pharmacy Department of Pharmacy Practice | |
| humma@uic.edu | ||
| Phone | 312-996-0886 | |
| Fax | 312-996-0379 | |
| Office | 125A PHARM m/c 886 | |
| US Mail | 833 South Wood Street, RM164 MC886, Chicago, IL 60612 | |
| Research Interests Dr. Cavallari's research focus is in the area of pharmacogenomics, particularly how genetic variants relate to cardiovascular drug response. Education |
| 2000 | Fellowship in Cardiovascular Pharmacogenomics The University of Florida, Gainesville, Florida |
|---|---|
| 1998 | ASHP Accredited Pharmacy Practice Residency Veterans Affairs Medical Center, Memphis, Tennessee |
| 1997 | Doctor of Pharmacy The University of Georgia, Athens, Georgia in affiliation with The Medical College of Georgia, Augusta, Georgia |
| 1991 | Bachelor of Science in Pharmacy, Summa Cum Laude The University of Georgia, Athens, Georgia |
| 1989 | Pre-pharmacy Georgia Southern University, Statesboro, Georgia |
| Current UIC Appointments |
| 2001 to present | Associate Professor, Department of Pharmacy Practice Member of the Graduate Faculty, College of Pharmacy |
|---|
| Representative Publications |
- Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MAG, Patel SR, Johnson JA. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010;87(4):459-64.
- Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford D, Lee MM, Chen CH, Motsinger-Rief A, Sagreiya H, Liu N, Wu AHB, Gage BR, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ on behalf of the IWPC. Warfarin pharmacogenetics: VKORC1 genotype as predictive as haplotype across three racial groups. Blood 2010;115(18):3827-34.
- Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 2012;22(2):152-8.
- Liu Y, Jeong HY, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH. Decreased warfarin clearance with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther 2012;91(4):660-5.
- Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 2012;13(16):1925-35.
